FMC is a $2.2B mid-cap ag-chem company with differentiated pipeline IP (Isoflex, Dodhylex, Rynaxypyr process-patents) and a balance sheet now under lender control. On April 20, FMC filed Amendment No. 6 to its $2B revolver — a covenant breach, forced conversion to a secured facility, and pledge of its core IP as collateral. Equity at $17.35 prices a binary coin flip on M&A. The filing supports a three-state distribution in which the market is mispricing the no-deal outcome, not the deal probability.

What the Filing Says

• Q1 2026 leverage covenant breached — the 6.00x limit was set only four months prior (Amendment No. 5, Dec 2025)
• Unsecured → Secured conversion — 15-bank syndicate took first-priority liens on Rynaxypyr process patents, Isoflex chemistry, all trademarks/copyrights, and equity in every material subsidiary
• Covenant schedule loosened — Dec 2026 raised from 5.50x to 6.75x. In four months, the leverage outlook deteriorated 1.25 turns of EBITDA vs. the banks' own prior model. Q1-Q3 2026 testing entirely suspended.
• Structural restrictions — any asset sale >$25M requires lender consent; buybacks prohibited; dividend frozen at $0.08/share through 2028 minimum
• Conflict-of-interest structure — Bank of America is simultaneously the syndication-agent secured lender AND FMC's M&A advisor (engaged Feb 5, 2026 with Goldman Sachs)

What the Market Thinks

Spot $17.35 (-52.5% 1Y, +22.5% 1M). IV rank 94th percentile, term structure inverted (136 near → 254 at 177d) — options imply a binary event before October. Fresh call activity concentrated at $18/$20 strikes with zero prior open interest. Short interest 16.2%.

Reverse-engineering the implied pricing against a deal/no-deal binary with $25/$10 outcomes: market implies ≈49% deal probability. We price ≈50%. No meaningful divergence on the deal side.

Why the Gap Exists

The market collapses "no deal" into distress ($10). Reality is three states, not two:

The standalone-survival state is defensible: covenant schedule explicitly allows 6.75x leverage through Q3 2027; destocking has bottomed (CTVA, UPL, Croda, Nufarm Q1 2026 data all confirm); India divestiture proceeds ($450M booked) are queued for debt paydown; Isoflex is launched across nine countries and Dodhylex is the first new herbicide mode of action in 30 years. FMC does not require a deal to clear $20.

Cross-ticker corroboration: ag-chem credit stress is idiosyncratic to FMC (and AVD, unrelated root cause). Six peers are deleveraging or expanding. On April 14, CTVA named Luke Kissam — former Albemarle CEO, former Bernhard Capital PE partner — as post-spin New Corteva CEO effective H2 2026, with $3.75M one-time equity inducement. Specialty-chem M&A platform-builder comp pattern, not steady-state. Timing aligns with FMC's strategic review. CTVA is tipping itself as the likely strategic buyer.

The $3/share gap lives in the quality of the no-deal state, not in deal probability.

Risks (Ranked)

1. Q1 EBITDA miss materially worse than banks' revised model — leverage >7.0x pushes distress-tail P from 25% toward 35-40%, edge collapses
2. CTVA Kissam signal proves narrative rather than intent — deal P reverts to base rate ≈30%, edge dies
3. Structural subordination — equity ranks behind $3.5B net debt and now secured IP claims; distress scenario floor could sit below $11
4. Rynaxypyr collateral value — additional patent settlements or litigation could compromise IP value underpinning the secured facility
5. Illiquid options chain — cannot hedge downside or size efficiently via derivatives (most strikes show 0 OI)

Catalysts

• ~May 6, 2026: Q1 2026 earnings release — leverage magnitude + destocking bottom confirmation
• Early May 2026: CTVA Q1 call — Kissam/Magro consolidation commentary
• Q2-Q3 2026: India divestiture closing (8-K Item 2.01)
• May-Jul 2026: Moody's/S&P rating action on structural subordination
• Jun-Oct 2026: BofA-led M&A process visibility (standard 4-6 months from Feb 5 kickoff)
• Jan-Feb 2027: Q4 2026 Compliance Certificate — binary covenant-pass vs. Amendment No. 7

What Would Change Our Mind

• Q1 2026 reported leverage >7.0x
• Amendment No. 7 filed before Q4 2026 covenant test
• CTVA Q1 transcript explicitly denies FMC interest or backs away from consolidation language
• No insider Form 4 P-code (open-market) buying by CEO, CFO, or Chief Counsel at prices <$18 during May-July
• Rating downgrade deeper than one notch (two-notch to mid-B or below would signal agency distress view)
• Any 8-K disclosing additional IP encumbrance, rescue financing at punitive terms, or standstill violations

Evidence